肌无力患者发病年龄与结局的关系
该多中心回顾性研究纳入中国3个中心2012至2022年住院的2574例肌无力患者,按发病年龄分为青少年型、早发型和晚发型。青少年型以0-4岁发病为主且多为眼肌症状,晚发型合并症更多且达到微小表现或更好状态的比例低于早发型。晚发型、胸腺异常和全身型肌无力与较差结局相关。
要点
- 青少年型肌无力多在0-4岁发病,以眼肌症状和女性为主。
- 晚发型肌无力合并症多,达到微小表现或更好状态的比例低于早发型。
- 晚发型、胸腺异常和全身型肌无力是结局较差的独立相关因素。
核心结论
- 肌无力患者的临床特征和预后因发病年龄不同而存在明显差异。
- 晚发型肌无力患者预后较差,青少年型中青春期发病者及晚发型患者为脆弱群体。
研究设计与样本
- 观察性、横断面、多中心、回顾性研究。
- 纳入中国3个肌无力中心2012年1月至2022年12月住院的2574例肌无力患者。
- 按发病年龄分为青少年型(<18岁)、早发型(≥18且<50岁)和晚发型(≥50岁)三组。
主要发现
- 2574例中青少年型1023例(39.7%),早发型568例(22.1%),晚发型983例(38.2%)。
- 青少年型发病高峰在0-4岁(61.9%),女性占58.3%,眼肌症状占90.2%。
- 晚发型男性占53.0%,合并症负担为40.6%,包括高血压、糖尿病和冠心病。
- 晚发型达到微小表现或更好状态的比例为66.7%,低于早发型的74.7%(p < 0.001)。
关键数值与推荐
- 青春期发病(OR 5.2 [95% CI 2.75-9.98])、胸腺增生(OR 11.4 [95% CI 5.64-22.99])和乙酰胆碱受体抗体阳性(OR 3.1 [95% CI 1.65-5.65])是青少年型继发全身化的危险因素。
- 晚发型肌无力(HR 0.8 [95% CI 0.69-0.91])、胸腺异常(HR 0.8 [95% CI 0.67-0.91];HR 0.7 [95% CI 0.61-0.88])和全身型肌无力(HR 0.8 [95% CI 0.71-0.96])与较差结局相关。
临床怎么用
- 对青春期发病的青少年型肌无力患者应警惕继发全身化风险。
- 对晚发型肌无力患者应重视合并症评估和预后判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Patients with myasthenia gravis (MG) exhibit significant heterogeneity based on age at disease onset. However, existing retrospective studies in China remain confined to single-center settings with limitations in sample size adequacy. The aim of this study was to compare clinical characteristics, treatment responsiveness, and long-term postintervention status of patients with MG across different onset ages. METHODS: This was an observational, cross-sectional, multicenter, retrospective study. We reviewed the medical records of patients diagnosed with MG who were hospitalized in 3 MG centers of China from January 2012 to December 2022. Demographic information, clinical characteristics, and therapeutic data were extracted from the electronic medical record system, and responsiveness to treatment was followed up. Patients were classified into 3 age subgroups: juvenile MG (age at onset <18 years), early-onset MG (onset ≥18 and <50 years), and late-onset MG (onset ≥50 years). Time to minimal manifestation (MM) or better status was assessed using Kaplan-Meier curves and Cox proportional hazards regression models. RESULTS: Among 2,574 patients with MG meeting inclusion criteria, 1,023 (39.7%) had juvenile MG, 568 (22.1%) had early-onset MG, and 983 (38.2%) had late-onset MG. Juvenile MG showed a peak onset at 0-4 years (61.9%), predominantly affecting female individuals (58.3%) and presenting mainly with ocular symptoms (90.2%). While most juvenile patients responded well to treatment, pubertal onset (OR 5.2 [95% CI 2.75-9.98]), thymic hyperplasia (OR 11.4 [95% CI 5.64-22.99]), and positive acetylcholine receptor antibodies (OR 3.1 [95% CI 1.65-5.65]) were risk factors of secondary generalization. In adults, late-onset MG was more common than early-onset MG, with male predominance (53.0%) and greater comorbidity burden (40.6%), including hypertension, diabetes mellitus, and coronary heart disease. The proportion of patients with late-onset MG (66.7%) achieving MM or better status was lower than that of patients with early-onset MG (74.7%) (p < 0.001). Multivariable analysis identified late-onset MG (HR 0.8 [95% CI 0.69-0.91]), thymic abnormalities (HR 0.8 [95% CI 0.67-0.91]; HR 0.7 [95% CI 0.61-0.88]), and generalized MG (HR 0.8 [95% CI 0.71-0.96]) as factors associated with poorer outcomes. DISCUSSION: This large cohort study highlights distinct clinical and prognostic differences in MG by age at onset. Pubertal-onset juvenile MG and late-onset MG represent vulnerable groups, with late-onset MG demonstrating poorer prognosis.
引用
- Huang X, Yu ZH, Cui Y, et al. Outcomes in Relation to the Age at Onset in Patients With Myasthenia Gravis. Neurology. 2025. PMID: 41264893. doi:10.1212/WNL.0000000000214428
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。